JOHNSON & JOHNSON
Q3 2025 13F Holdings
- Locationnew brunswick, NJ
- Num holdings
20
- Value ($000)
$503,700
- Date Filed11/13/2025
- Form type13F-HR
- CIK0000200406
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
PTGX Protagonist Therapeutics Inc. | COM | 74366E102 | $162.70 M | 32 % | 2,449,183 | ||
NBTX Nanobiotix S.A. | SPONSORED ADS | 63009J107 | $106.23 M | 21 % | 5,623,816 | ||
MeiraGTx Holdings plc | COM | G59665102 | $54.66 M | 11 % | 6,641,064 | ||
RAPP Rapport Therapeutics, Inc. | COM | 75383L102 | $53.00 M | 11 % | 1,784,517 | ||
CVRX CVRx, Inc. | COM | 126638105 | $33.11 M | 7 % | 4,103,430 | ||
LEGN Legend Biotech Corporation | SPONSORED ADS | 52490G102 | $26.56 M | 5 % | 814,586 | ||
CTNM Contineum Therapeutics Inc. | CL A | 21217B100 | $23.26 M | 5 % | 1,979,173 | ||
PRCT Procept BioRobotics Corporation | COM | 74276L105 | $12.77 M | 3 % | 357,939 | ||
XNCR Xencor, Inc. | COM | 98401F105 | $8.77 M | 2 % | 748,062 | ||
ARWR Arrowhead Pharmaceuticals, Inc. | COM | 04280A100 | $8.54 M | 2 % | 247,598 |
Rows Per Page
10
- 10
- 50
- 100